IVIM Health review: pricing, fine print, and how it ranks

The price, in words

On tirzepatide, IVIM Health prices out at $278 a month all-in at the 10 mg maintenance basis, dose-scaled from a $208 entry, including the mandatory $75/mo membership. That ranks #3 of 17 priced compounded programs — $63 a month above the field's floor (NexLife at $215). Semaglutide runs $224 a month all-in at the standing rate ($149 on intro/plan terms). (#11 of 19 on our semaglutide basis)

What the fine print says

The number to hold onto is the all-in figure: the $75 monthly membership is mandatory, recurs, and belongs in any comparison — advertised medication-only prices here understate the bill. Pricing is dose-scaled: the $208 entry figure rises to $278 by the 10 mg tier, so budget the maintenance number, not the ad. The medication figure requires a mandatory $75/mo membership for the duration of the plan, and tirzepatide is dose-scaled: the $208 entry rate rises to $278 all-in at the 10 mg maintenance tier.

Pharmacy & transparency

Price evidence: Source-verified, last verified 2026-08-05. The dispensing pharmacy is not named publicly — the single most common transparency gap in this market. Ask which pharmacy fills the prescription, whether it is 503A or 503B, and whether a certificate of analysis is available; our pharmacy guide explains what each answer means.

The dose ladder, priced rung by rung

IVIM Health's ladder climbs with the dose: $208 at the 2.5 mg entry, rising through intermediate tiers to about $278 by the 10 mg maintenance rung — a $70 spread between the price in the ad and the price at the dose most patients hold. Budget the ladder, not the entry: a standard four-month titration lands somewhere between $832 and $1,112 depending on how the intermediate tiers fall, and every maintenance month after that bills at the $278 tier — the figure we rank on, because it is the one that predicts a year of spending. Escalating past 10 mg for more effect raises the bill again on a scaled plan, which is worth weighing before a plateau forces the question.

What the first year actually bills

Run the calendar and IVIM Health's year one totals $3,219 at the standing rate: a titration stretch billed between $208 and $278, then roughly eight to nine months at the $278 maintenance tier. No prepaid tier is published, so the standing rate is the only rate — simpler, and fully flexible. Benchmarked to the verified floor, the year costs $756 more than NexLife's $2,580 — the premium a buyer should be able to name a reason for. Brand context: Zepbound's comparable first year via LillyDirect runs about $5,188 on a standard titration, and $5,388 for a full year already at maintenance.

The 24-month view

On a two-year view, the standing plan totals $6,672 at IVIM Health. The same 24 months cost $5,160 at the verified floor and $10,776 on brand Zepbound at maintenance — bookends worth writing on the first invoice.

The semaglutide side of the house

On the cheaper molecule, IVIM Health bills $224/month all-in, ranking #11 of 19 on our verified semaglutide basis — against a field floor of $133 (Oak Longevity, with state limits) and brand Wegovy's flat $349. The in-house premium for stepping up to tirzepatide is $54/month — the local price of SURMOUNT-5's 20.2%-vs-13.7% head-to-head result, and a switch that stays inside one program's intake and pharmacy relationships.

Where it sits in the market

On the verified tirzepatide board, IVIM Health's $278 all-in rate ranks #3 of 17: $63/month above the NexLife floor; one rung cheaper sits Yucca Health at $258 (a $20/mo gap); one rung pricier is Mochi Health at $278. Against the FDA-approved benchmark, the same year costs $2,052 less than Zepbound's $449 maintenance tier — the discount a buyer is accepting compounded-product risk to collect. The full board, sortable and dated, is the tirzepatide ranking.

Three buyers, priced honestly

The week-one starter. First month at the 2.5 mg rung: $208, before the ladder scales toward $278. The 10 mg maintainer. Settled at maintenance, the run-rate is $278/month, $3,336/year — the figure that should anchor any comparison, since it describes years two and three, not the promo. The prepay optimizer. No prepaid tier exists here; the committed-money crowd should compare Found's $169 and NexLife's $186 twelve-month effectives instead.

Nearest alternatives at this price point

Shopping the immediate neighborhood, the closest verified substitutes are Mochi Health at $278 (flat at every dose, named pharmacy); Found at $289 (flat at every dose, no membership, prepaid to $169); ShedRx at $289 (no membership) — each linked matchup runs the full head-to-head arithmetic on this exact question.

State availability

IVIM Health publishes availability of: not published. State-by-state context, exceptions, and city coverage live in the 51-state cost guides.

Five questions before checkout

Whatever the marketing says, get answers to: (1) the all-in monthly price at 10 mg and at 12.5 mg, in writing, including every mandatory fee; (2) whether the price changes at any rung of the dose ladder, and the exact tier schedule; (3) which pharmacy, by name, fills the prescription — and whether it's 503A or 503B, licensed for your state, with a certificate of analysis available; (4) the cancellation mechanics — deadline relative to renewal, written-confirmation availability, and whether any membership cancels separately. A program that answers all five plainly has already told you most of what this review can.

Visit IVIM Health — verify current pricing →Opens the provider’s own pricing page; our figures were captured 2026-08-05.

Bottom line

IVIM Health is a top-tier price pick on tirzepatide. For context, the verified market floor is $215/mo compounded tirzepatide and $133/mo compounded semaglutide, with brand Zepbound at $449/mo and Wegovy at $349/mo at maintenance.